Loading clinical trials...
Loading clinical trials...
A Phase I, Open Label, Dose Escalation Study of a New Formulation of Calcitriol (DN-101) for Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Conditions
Interventions
DN-101
Locations
2
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Oregon Health & Science University
Portland, Oregon, United States
Start Date
March 1, 2002
Last Updated
July 28, 2009
NCT07213804
NCT00026884
NCT07159659
NCT07169851
NCT06662786
NCT07191730
Lead Sponsor
Novacea
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions